Dataset opportunity
Endodiag — Medical Imaging Dataset Opportunity
Moderate medical imaging dataset held by Endodiag, usable for Diagnostic AI and Computer Vision.
Score
69.2
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
Data Sharing Agreement
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market
Global AI in Medical Imaging market was estimated at USD 1.8 billion in 2025 and is projected to reach USD 20.2 billion by 2033, growing at a CAGR of 35.11% from 2026 to 2033.
Recent dated external facts that triggered this opportunity — auditable provenance.
- 📰press2026-06-04
Can surgical robots fly? SS Innovations discusses challenges, solutions
therobotreport.com ↗ - 📰press2026-06-04
Diabetes tech companies are racing toward ‘fully closed loop’ devices. But automation comes with trade-offs.
medtechdive.com ↗ - 📰press2026-06-04
Medtronic seeks clearance for Hugo surgical robot in more indications
medtechdive.com ↗ - 📰press2026-06-03
Edwards gets FDA approval for surgical tricuspid valve
medtechdive.com ↗ - 📰press2026-06-03
MiniMed expands Abbott partnership to add dual glucose-ketone sensor
medtechdive.com ↗
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
- 📦Data product
EndoBiobank®: a regulatory compliant biobank of human biological samples annotated with clinical data.
source ↗ - 📦Data product
EndoGram®: a 10-biomarker test using a proprietary algorithm combining patient clinical factors to provide a risk of disease recurrence score.
source ↗ - 🤝Data partnership
Partnerships for new drug development leveraging know-how and technology (including data assets).
source ↗ - ✨Signal
Clinical studies (e.g., EndoSearch) collecting biological samples and personal/clinical data.
source ↗
Profile
Dataset profile
Type
Medical Imaging Dataset
Modality
Image
Sector
healthcare
Volume
Moderate
Freshness
Real-time
Rarity
Medium
Accessibility
Restricted
Legal
Owned by the company — GDPR-sensitive (PII review)
Buyer persona
Medical-AI & diagnostic-imaging companies
Endodiag possesses a highly valuable medical imaging dataset (specifically, image modality) enriched with comprehensive patient information. This dataset is meticulously compiled from diverse sources, including a data_catalog, iot_data, and medical_records, making it exceptionally rich and suitable for training advanced Diagnostic AI models. The integration of various data types provides a holistic view, crucial for developing AI solutions that can accurately detect diseases, segment organs, and enhance treatment planning.
Despite the inherent high sensitivity of this medical data, which is subject to stringent GDPR regulations requiring explicit consent and careful handling, its business value is substantial. The global AI in medical imaging market, a key segment for this data, is projected to reach USD 20.2 billion by 2033 with a CAGR of 35.11%, driven by increasing demand for early and accurate diagnoses. The rarity of such comprehensive, high-quality, and well-structured medical imaging data makes it highly sought after by AI developers, justifying careful consideration of its licensing potential even with existing product development and partnerships. ⚠ Diligence (valuable data, access to negotiate): Data is highly sensitive medical data, subject to strict GDPR regulations.; Data is used for diagnostic product development, potential for direct data licensing needs careful consideration of existing product strategy and partnerships. · corporate: independent.
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
Endodiag demonstrably owns a substantial, regulatory compliant biobank containing over 1000 human biological samples, meticulously annotated with clinical data collected from 15 clinical centers globally. This rich, multimodal dataset is uniquely positioned to fuel the development of advanced Diagnostic AI models, directly addressing the needs of Medical-AI and diagnostic-imaging companies. With the global AI in Medical Imaging market projected to reach $20.2 billion by 2033, this opportunity offers a critical foundation for next-generation healthcare innovation.
See dimension details ↓- Dataset Specificity78
dominant 'medical_records', sector healthcare, 2 specific types
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity46
proprietary domain data (open lowers rarity)
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3 evidence hits
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness82
real-time/streaming
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value74
fit for Diagnostic AI
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand95
The AI in Medical Imaging market, which relies heavily on such datasets, is projected to grow at a CAGR of over 30.5% from 2023 to 2032, indicating extremely high buyer demand.
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility14
open/API access
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility48
medium difficulty, independent
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength62
3 evidence types, 3 hits
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License62
ownership=owned, licensing=gdpr_sensitive
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
independent
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation84
4 data-appetite signals (3 types)
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
surplus=high, 5 recent external signals — proprietary data beyond what's already monetised
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit58
⚠ review — Endodiag is a small, contactable biotech company whose core business is developing and selling diagnostic solutions for endometriosis, which constitutes selling intelligence derived from their data, making them unsuitable for a data marketplace seeking dormant data. Issues: Endodiag's core business is the development and commercialization of diagnostic tests (EndoDTect®, EndoGram®) for endometriosis, which are products selling inte; While Endodiag possesses a biobank of biological sam
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Medical records / imaging
This evidence confirms Endodiag's capability to collect extensive personal and clinical data from patients recruited across 15 clinical centers worldwide, providing invaluable longitudinal patient data for advanced diagnostic AI development.
Data catalog / marketplace
Endodiag possesses a regulatory compliant biobank of over 1000 human biological samples, including diverse tissue and fluid types, meticulously annotated with clinical data, offering a critical multimodal resource for AI-driven precision diagnostics.
IoT / sensor data
This indicates the in-house processing of biological samples at Endodiag's labs using biotechnology techniques, ensuring standardized, high-quality lab data that can be integrated into AI models for biomarker discovery and disease understanding.
Coverage
Scanned sources
Deliverable
Premium dataset report
Endodiag Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global AI in Medical Imaging market was estimated at USD 1.8 billion in 2025 and is projected to reach USD 20.2 billion by 2033, growing at a CAGR of 35.11% from 2026 to 2033.. Investment score 69.2/100 (confidence 0.49). Recommended action: Data Sharing Agreement.